Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Inclusion Criteria:

• Age ≥18 years.

• Has pancreatic ductal adenocarcinoma

• Has resectable disease at the time of diagnosis

• Has not received any systemic therapy for pancreatic ductal adenocarcinoma

• Has stage ≤ IIb disease at time of diagnosis and enrollment

• Elevated tumor marker, CA (carbohydrate antigen) 19-9 >200

• ECOG performance status 0 or 1

• Patient must have adequate organ function defined by the study-specified laboratorytests.

• Must use acceptable form of birth control while on study.

• Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

Patients who have received any prior chemotherapy, radiotherapy or investigational agents for pancreatic cancer.

• Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2,anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitoryT-cell receptor (e.g., CTLA-4, OX 40, CD137).

• Has received prior therapy with FAK inhibitor.

• Woman who are pregnant or breastfeeding.

• Have received a live vaccine or live-attenuated vaccine within 30 days prior tostudy drug.

• Is currently or has participated in another investigational study within 4 weeksprior to receiving study drug.

• History or current use of immunosuppressive medications within 7 days prior to studymedications.

• Has a known additional malignancy that is progressing or has required activetreatment within the past 2 years or that is expected to require active treatmentwithin two years.

• Has active autoimmune disease that has required systemic treatment in the past 2years.

• Has a history of (non-infectious) pneumonitis/interstitial lung disease or currentpneumonitis.

• Has an active infection requiring systemic therapy.

• Infection with HIV or hepatitis B or C.

• Patient with uncontrolled intercurrent illness including, but not limited to,uncontrolled infection, symptomatic congestive heart failure, unstable anginapectoris, cardiac arrhythmia, or psychiatric illness/social situations that wouldlimit compliance with study requirements.

• Known allergy or hypersensitivity to the study drugs.

• Received any growth factors including, but not limited to, granulocyte-colonystimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of study drugadministration.

• Has history of any organ transplant, including corneal transplants.